This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

YRC Worldwide, LDK Solar: Midday Volume Plays

NEW YORK (TheStreet) -- Several small-cap stocks were moving on above-average volume during Monday's session.

Qiao Xing Mobile Communication (QXM) jumped by 37 cents, or 16.2%, to $2.65 in the absence of any company-specific news, two session after reporting second-quarter results. Investors posting on Internet message boards noted an MSN Money article that called Qiao Xing a great play under $5 for those looking to cash in on expectations that economic growth in China will mean more people joining mobile networks. Volume topped 600,000 shares, compared to the three-month average daily volume of 70,000, according to Yahoo! Finance.

YRC Worldwide (YRCW) plummeted by 37 cents, or 16.2%, to $2.65 after the company said its exchange offer, with full participation, would see noteholders exchange approximately $536.8 million in notes plus accrued and unpaid interest for shares of common stock and new class A convertible preferred stock. Together on an as-if converted basis, it would represent 95% of YRC Worldwide's common stock. In separate news, RBC Capital Markets said in a research note that the firm believes the stock has no value and therefore their price target is zero. Volume topped 32 million shares, compared to the 50-day average daily volume of 10 million, according to the Nasdaq.

LDK Solar (LDK) lost 37 cents, or 16.2%, to $2.65 after Q-Cells (QCE), one of the world's largest makers of solar cells, terminated a supply agreement with the company. Q-Cells said LDK did not fulfill "significant contractual obligations" with regard to the supply agreement concluded in 2007. Volume topped 7 million shares, compared to the three-month average daily volume of 3.2 million, according to Yahoo! Finance.

GTx (GTXI) tumbled by 37 cents, or 16.2%, to $2.65 after the Food and Drug Administration rejected acapodene, asking GTx for additional clinical data on the drug's efficacy and safety as well as proof that treatment with the drug does not cause prostate tumors to grow or shorten a patient's overall survival. Volume topped 4 million shares, compared to the 50-day average daily volume of 468,000, according to the Nasdaq.

-- Written by Robert Holmes in New York.

Check out all of Monday's high-volume, under-$5 stocks at the Dollar Store

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs